您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Olopatadine HCl(ALO4943A KW4679)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Olopatadine HCl(ALO4943A KW4679)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Olopatadine HCl(ALO4943A KW4679)图片
CAS NO:140462-76-6
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)373.87
FormulaC21H23NO3.HCl
CAS No.140462-76-6
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 75 mg/mL (200.6 mM)
Water: 13 mg/mL (34.8 mM)
Ethanol: 8 mg/mL (21.39 mM)
Other info

Chemical Name: 2-[(11Z)-11-[3-(Dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride

InChi Key: HVRLZEKDTUEKQH-NOILCQHBSA-N

InChi Code: InChI=1S/C21H23NO3.ClH/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24;/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24);1H/b18-8-;

SMILES Code: O=C(O)CC1=CC=C(OCC2=CC=CC=C2/C3=C/CCN(C)C)C3=C1.[H]Cl

Synonyms

ALO4943A; KW-4679; ALO-4943A; KW4679; Olopatadine HCl; Olopatadine Hydrochloride; Pataday; Patanase; KW 4679; ALO 4943A; ALO4943A

实验参考方法
In Vitro

In vitro activity: Olopatadine is one of the second-generation histamine H1 receptor antagonists that are treated for allergic disorders. Olopatadine significantly inhibited the ear swelling and the increased production of IL-4, IL-1beta, IL-6, GM-CSF and NGF in the lesioned ear. Olopatadine was highly and rapidly absorbed in healthy human volunteers. The urinary excretion of olopatadine accounted for not less than 58% and the contribution of metabolism was considerably low in the clearance of olopatadine in humans. Olopatadine is one of the few renal clearance drugs in antiallergic drugs. Olopatadine was shown to be useful for the treatment of allergic rhinitis and chronic urticaria in double-blind clinical trials. AL-4943A inhibits histamine release in a concentration-dependent fashion (IC50 = 559 microM) from human conjunctival mast cell preparations in vitro. Passive anaphylaxis in guinea pig conjunctiva was attenuated by AL-4943A applied 30 min prior to intravenous or topical ocular antigen challenge (ED50 values 0.0067% and 0.0170%, w/v, respectively).

In Vivo
Animal model
Formulation & Dosage
References

Pharmacology. 2005 Dec;75(1):45-52; Jpn J Pharmacol. 2002 Apr;88(4):379-97.